CN114409756A - 一种牙鲆补体成分C3（PoC3）的应用 - Google Patents

一种牙鲆补体成分C3（PoC3）的应用 Download PDF

Info

Publication number
CN114409756A
CN114409756A CN202210070638.7A CN202210070638A CN114409756A CN 114409756 A CN114409756 A CN 114409756A CN 202210070638 A CN202210070638 A CN 202210070638A CN 114409756 A CN114409756 A CN 114409756A
Authority
CN
China
Prior art keywords
complement component
protein
val
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210070638.7A
Other languages
English (en)
Other versions
CN114409756B (zh
Inventor
李墨非
吴蒙
贾贝贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Oceanology of CAS
Original Assignee
Institute of Oceanology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Oceanology of CAS filed Critical Institute of Oceanology of CAS
Priority to CN202210070638.7A priority Critical patent/CN114409756B/zh
Publication of CN114409756A publication Critical patent/CN114409756A/zh
Application granted granted Critical
Publication of CN114409756B publication Critical patent/CN114409756B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及分子生物学领域，具体的说是一种牙鲆补体成分C3(PoC3)的应用。牙鲆补体成分C3(PoC3)在制备杀菌剂中的应用。本发明补体成分C3是来自于牙鲆补体***的一种天然蛋白。该补体成分C3蛋白可制备为杀菌剂，其制备过程简单，对环境和鱼体均无安全隐患，进而所得蛋白在抗细菌感染中具有应用潜能。

Description

一种牙鲆补体成分C3（PoC3）的应用
技术领域
本发明涉及分子生物学领域，具体的说是一种牙鲆补体成分C3(PoC3) 的应用。
背景技术
补体***由大约35种蛋白质组成，它们存在于血清、组织液和细胞膜表面。补体***可以通过三种不同的途径激活，包括经典途径、凝集素途径和旁路途径。C3是补体***的中心因子，所有三种补体激活途径都需有 C3转化酶的形成。在补体激活的级联反应中，C3转化酶裂解C3产生C3a 和C3b，C3b参与C5转化酶的形成。C5转化酶将C5裂解为C5a和C5b，C5b参与膜攻击复合物(MAC)的组装。MAC在病原体的表面打孔，导致受感染细胞的破坏和外来病原体的死亡。C3在补体***中起重要作用，广泛参与先天免疫和适应性免疫。补体成分C3已在多种鱼类中发现，但是，在牙鲆中C3功能和应用性研究尚不十分清楚。
发明内容
本发明目的在于提供一种牙鲆补体成分C3(PoC3)的应用。
为实现上述目的，本发明采用的技术方案为：
一种补体成分C3的应用，牙鲆补体成分C3(PoC3)在制备杀菌剂中的应用。
所述补体成分C3(PoC3)为序列表SEQ ID No.1中氨基酸序列所示。
所述补体成分C3在制备哈维氏弧菌(Vibrio harveyi)或海豚链球菌(Streptococcus iniae)的杀菌剂中的应用。
所述补体成分C3为以牙鲆血清为原材料，用沉降剂沉降血清，所得蛋白沉淀用20mM Tris-HCL缓冲液(pH7.4)重悬，将重悬液加入到Mono Q HR5/5阴离子交换色谱柱中，梯度洗脱收集含有C3蛋白的洗脱液进行混合浓缩并重悬在20mM的2-吗啉乙磺酸(MES)(pH5.8)中，然后将重悬液加入到Mono S HR5/5阳离子交换色谱柱中，梯度洗脱收集含有C3蛋白的洗脱液进行透析浓缩后，即为序列表SEQ ID No.1所示的补体成分C3；
所述沉降剂为终浓度的16％的聚乙二醇、20mM EDTA、10mM苄脒、 1mM苯甲基磺酰氟。
所述梯度洗脱时洗脱液为(0-1M)的NaCl溶液。
进一步的说：
1)以阴离子交换色谱柱获得初步纯化的牙鲆补体C3蛋白
取牙鲆血清(5ml)与沉降剂等体积混匀，在4℃下沉降30min，收集蛋白沉淀，用20mM Tris-HCL缓冲液(pH 7.4)重悬，将重悬液加入到Mono Q HR5/5阴离子交换色谱柱中，借助高效液相色谱仪，使用NaCl溶液(0-1M) 进行梯度洗脱，然后将洗脱液进行聚丙烯酰胺凝胶电泳(SDS-PAGE)分析，并收集含有C3蛋白的洗脱液，即为初步纯化的补体成分C3蛋白；
2)以阳离子交换色谱柱获得完全纯化的牙鲆补体C3蛋白
将上述步骤1)收集的含有C3蛋白的洗脱液进行混合、浓缩并重悬在 20mM的2-吗啉乙磺酸(MES)(pH5.8)中，然后将重悬液加入到Mono S HR5/5阳离子交换色谱柱中，用NaCl溶液(0-1M)对初步纯化的补体成分C3蛋白进行梯度洗脱，收集洗脱液进行聚丙烯酰胺凝胶电泳 (SDS-PAGE)分析，并进行质谱分析，将质谱结果与序列表SEQ ID No.1 所示的牙鲆补体成分C3序列进行比对，确定纯化蛋白为牙鲆C3蛋白，最后将含有牙鲆C3蛋白的洗脱液进行透析浓缩后，即为牙鲆补体C3蛋白。
本发明具有如下优点：
本发明补体成分C3是来自于牙鲆补体***的一种天然蛋白。该补体成分C3蛋白可制备为杀菌剂，其制备过程简单，对环境和鱼体均无安全隐患，且对哈维氏弧菌和海豚链球菌产生显著的杀菌效应，进而所得蛋白在抗细菌感染中具有应用潜能。
附图说明
图1为本发明实施例提供的牙鲆补体成分C3(PoC3)蛋白对哈维氏弧菌和海豚链球菌的杀菌效应。
具体实施方式
下面结合实施例对本发明作进一步说明。实施例旨在对本发明进行举例描述，而非以任何形式对本发明进行限制。
实施例1
补体成分C3蛋白的纯化
(1)补体成分C3蛋白的纯化
本发明的补体成分C3通过从牙鲆血清中纯化获得，其序列为序列表 SEQ ID No.1中的氨基酸序列。
序列表SEQ ID No.1为：
MGRTQLWLLASLAFASIASLVDGAPLKVMSAPNLLRVGTTENIFVECQD CTGGDIKVDINVMNHPTKVNRLATTSVTLTSGQNFQALGQIRIPAGGFSK DPRLKQYVYLQAQFPDRLLEKVVLVSFQSGFIFIQTDKTIYTPNSKVLYR MFAVTPTMEPVERDEQIQNEASIAIEFVTPEDIVLPLDPVSLKSGIHSGEY KLAEIVSPGLWKVVAKFHSNPQESFSAEFEVKEYVLPSFEVKLTSTSPFFY VESEDLTINIKATYLFGEEVSGTAYVVFGVVLEGEKKSFPSSLQRISIDNGI GLVQLKRQQITQSFQDINALVGNSLFVAVSVLTESGGEMVEAELRGIQIV KSPYTIHFRKTPKYFKPGMTFDIVVEVTNPDETPAQGVAVVVDPGAVKGL TAANGFAKLTVNTMAGVARLPVTAKTNDPLIPLARQAEATMTALPYNTK SNNYIHIGVDTAELELGDNLKVNLNLKKQSNQDTDITYLILSRGQLIQSG RYRTRGQVLISLIIPITKVMLPSFRIVAYYHLDDNEVVSDSVWVDVKDSC MGTLKLESSRPAPSYEPRKMFGLKVTGVPEAMVGLVAVDKGVYVLNNK HRITQKKVWDIIEKYDTGCTPGGGKNSMSVFYDAGLLFESSAASGTPYR QELKCPVPARRKRATTVMNVTTTLVNKYKNELQRECCSEGMKETILSYT CEVRSEYILDGASCVDAFLHCCKEMENLRGEMKQDQLDLARSEEDDSY MDSNEISSRTKFPESWLWSDIQLPACPQQTPNCESTSFMKPVPLQDSITTW QFTGISLSRTHGICVGEPLEVIVRKDFFIDLRLPYSAVRGEQLEIKAILHNY SPDVITVRVDLIEEENVCSVASKHTRYRQEVKVGQQTTRSVPFVIIPMKE GQFNIEVKAAVKDSSLNDGIVKVLRVVPEGVLIKQPQIITLDPSKTGGEQ VEILNSRIPRKDMVPNTPTTTQISVTGRENVGQLVENAISGQSMGTLIYQP SGCGEQNMIHMTLPVIAATYLDKTNQWETVGFQKRNEALQHIKTGYTN ELAYRKKDGSFSVWASHGSSSWLTAYVAKVFAMANSLVAVQNNVICDAV KYLILNAQQPDGVFKEVGRVAHGEMIGDVRGTDSEASMTAFCLIAMQES RTLCAATVNSLPGSVEKSVLYLERRLESLTNPYAVAITSYALANEGRLNKD VLYKFASPELSHWPVPKGRVYTLEATAYALLALVKTKDFEKARPIVRWFS QQQKVGGGYGSTQATIIVYQAVAEYWAAAKEPEYDLNVDILLPGRSKPE KIVLNADNSYTTRTSKINDINQDVKVTAKGTGEATVTMVSLYYALPQKK ESDCQKFNMSVELIPERIDADESIFKLKIEVLYKDKERDATMSILDIGLLTG FTPNTNDLNLLSKGRARTLAKYEMNTLLSEKGSLIIYLDKVSHTRPEEITF RVHQKMKVGVLQPAAVSVYEYYDQTQCVQFYHPQRKAGQLLRLCRNE ECTCAEENCSMQKKGKISNDQRIEKSCETTPTSKIDFVYKVRLEEFTDGG STDIYTMRILEGIKEGSYDVAPQGKLRTFLSYQHCRESLDLGKGKMYLIM GTSKDIHRDDQNESYHYVLGERTWIEYWPTEAECQTEEHRPTCLGLQQ MVQQYLLFGCQQ
(a)序列特征：
·长度：1655
·类型：氨基酸序列
·链型：双链
·拓扑结构：线性
(b)分子类型：蛋白质
(c)假设：否
(d)反义：否
(e)最初来源：牙鲆血清
取5ml牙鲆血清，与沉降剂混匀，在4℃下沉降30min，收集蛋白沉淀，用20mM Tris-HCL缓冲液(pH7.4)重悬，将重悬液加入到Mono Q HR5/5 阴离子交换色谱柱(购于美国GEHealthcare公司)中，借助高效液相色谱仪，使用NaCl溶液(0-1M)进行梯度洗脱，然后将洗脱液进行聚丙烯酰胺凝胶电泳(SDS-PAGE)分析，根据C3蛋白分子量大小分析并收集含有C3蛋白的洗脱液，即为初步纯化的补体成分C3蛋白。将收集的含有C3蛋白的洗脱液进行混合、浓缩并重悬在20mM的2-吗啉乙磺酸(MES)(pH 5.8) 中，然后将重悬液加入到Mono S HR5/5阳离子交换色谱柱(购于美国GE Healthcare公司)中，用NaCl溶液(0-1M)再次对PoC3进行梯度洗脱，按洗脱液梯度收集每个浓度的洗脱液进行聚丙烯酰胺凝胶电泳 (SDS-PAGE)分析，并进行质谱分析，将质谱结果与序列表SEQ ID No.1 所示的牙鲆补体成分C3序列进行比对，确定纯化蛋白为牙鲆C3蛋白，最后将含有牙鲆C3蛋白的洗脱液进行透析浓缩后，即为牙鲆补体C3蛋白。
所述沉降剂为终浓度的16％的聚乙二醇、20mM EDTA、10mM苄脒、 1mM苯甲基磺酰氟。
实施例2
牙鲆补体成分C3蛋白(PoC3)对哈维氏弧菌和海豚链球菌的杀菌效应：
步骤1)细菌的培养
将哈维氏弧菌接种于LB培养基，海豚链球菌接种于TSB培养基,将上述细菌28℃培养至OD600约为0.8，收集菌体，用无菌PBS清洗3遍，然后将其重悬于PBS中至终浓度为106CFU/ml。
步骤2)牙鲆补体成分C3蛋白(PoC3)杀菌活性检测
将上述步骤1)中细菌稀释液与浓缩后经PBS配置至终浓度为50μg/ml 的实施例1中纯化的PoC3、相同浓度的牛血清白蛋白(BSA)或PBS(对照组)混合，室温下孵育1h。为计算准确将混合液梯度稀释，均匀涂在固体LB或TSB平板上，放于28℃培养箱中培养12h，对平板进行计数。结果表明，PoC3可以直接杀伤哈维氏弧菌和海豚链球菌，显著的降低细菌的存活率(图1)，具有较强的杀菌效应，而BSA组和对照组处理的细菌存活率没有差异，因此补体成分C3蛋白(PoC3)能够作为一种天然杀菌剂应用于牙鲆细菌性疾病的防治。
序列表
<110> 中国科学院海洋研究所
<120> 一种牙鲆补体成分C3（PoC3）的应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1655
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Met Gly Arg Thr Gln Leu Trp Leu Leu Ala Ser Leu Ala Phe Ala Ser
1 5 10 15
Ile Ala Ser Leu Val Asp Gly Ala Pro Leu Lys Val Met Ser Ala Pro
20 25 30
Asn Leu Leu Arg Val Gly Thr Thr Glu Asn Ile Phe Val Glu Cys Gln
35 40 45
Asp Cys Thr Gly Gly Asp Ile Lys Val Asp Ile Asn Val Met Asn His
50 55 60
Pro Thr Lys Val Asn Arg Leu Ala Thr Thr Ser Val Thr Leu Thr Ser
65 70 75 80
Gly Gln Asn Phe Gln Ala Leu Gly Gln Ile Arg Ile Pro Ala Gly Gly
85 90 95
Phe Ser Lys Asp Pro Arg Leu Lys Gln Tyr Val Tyr Leu Gln Ala Gln
100 105 110
Phe Pro Asp Arg Leu Leu Glu Lys Val Val Leu Val Ser Phe Gln Ser
115 120 125
Gly Phe Ile Phe Ile Gln Thr Asp Lys Thr Ile Tyr Thr Pro Asn Ser
130 135 140
Lys Val Leu Tyr Arg Met Phe Ala Val Thr Pro Thr Met Glu Pro Val
145 150 155 160
Glu Arg Asp Glu Gln Ile Gln Asn Glu Ala Ser Ile Ala Ile Glu Phe
165 170 175
Val Thr Pro Glu Asp Ile Val Leu Pro Leu Asp Pro Val Ser Leu Lys
180 185 190
Ser Gly Ile His Ser Gly Glu Tyr Lys Leu Ala Glu Ile Val Ser Pro
195 200 205
Gly Leu Trp Lys Val Val Ala Lys Phe His Ser Asn Pro Gln Glu Ser
210 215 220
Phe Ser Ala Glu Phe Glu Val Lys Glu Tyr Val Leu Pro Ser Phe Glu
225 230 235 240
Val Lys Leu Thr Ser Thr Ser Pro Phe Phe Tyr Val Glu Ser Glu Asp
245 250 255
Leu Thr Ile Asn Ile Lys Ala Thr Tyr Leu Phe Gly Glu Glu Val Ser
260 265 270
Gly Thr Ala Tyr Val Val Phe Gly Val Val Leu Glu Gly Glu Lys Lys
275 280 285
Ser Phe Pro Ser Ser Leu Gln Arg Ile Ser Ile Asp Asn Gly Ile Gly
290 295 300
Leu Val Gln Leu Lys Arg Gln Gln Ile Thr Gln Ser Phe Gln Asp Ile
305 310 315 320
Asn Ala Leu Val Gly Asn Ser Leu Phe Val Ala Val Ser Val Leu Thr
325 330 335
Glu Ser Gly Gly Glu Met Val Glu Ala Glu Leu Arg Gly Ile Gln Ile
340 345 350
Val Lys Ser Pro Tyr Thr Ile His Phe Arg Lys Thr Pro Lys Tyr Phe
355 360 365
Lys Pro Gly Met Thr Phe Asp Ile Val Val Glu Val Thr Asn Pro Asp
370 375 380
Glu Thr Pro Ala Gln Gly Val Ala Val Val Val Asp Pro Gly Ala Val
385 390 395 400
Lys Gly Leu Thr Ala Ala Asn Gly Phe Ala Lys Leu Thr Val Asn Thr
405 410 415
Met Ala Gly Val Ala Arg Leu Pro Val Thr Ala Lys Thr Asn Asp Pro
420 425 430
Leu Ile Pro Leu Ala Arg Gln Ala Glu Ala Thr Met Thr Ala Leu Pro
435 440 445
Tyr Asn Thr Lys Ser Asn Asn Tyr Ile His Ile Gly Val Asp Thr Ala
450 455 460
Glu Leu Glu Leu Gly Asp Asn Leu Lys Val Asn Leu Asn Leu Lys Lys
465 470 475 480
Gln Ser Asn Gln Asp Thr Asp Ile Thr Tyr Leu Ile Leu Ser Arg Gly
485 490 495
Gln Leu Ile Gln Ser Gly Arg Tyr Arg Thr Arg Gly Gln Val Leu Ile
500 505 510
Ser Leu Ile Ile Pro Ile Thr Lys Val Met Leu Pro Ser Phe Arg Ile
515 520 525
Val Ala Tyr Tyr His Leu Asp Asp Asn Glu Val Val Ser Asp Ser Val
530 535 540
Trp Val Asp Val Lys Asp Ser Cys Met Gly Thr Leu Lys Leu Glu Ser
545 550 555 560
Ser Arg Pro Ala Pro Ser Tyr Glu Pro Arg Lys Met Phe Gly Leu Lys
565 570 575
Val Thr Gly Val Pro Glu Ala Met Val Gly Leu Val Ala Val Asp Lys
580 585 590
Gly Val Tyr Val Leu Asn Asn Lys His Arg Ile Thr Gln Lys Lys Val
595 600 605
Trp Asp Ile Ile Glu Lys Tyr Asp Thr Gly Cys Thr Pro Gly Gly Gly
610 615 620
Lys Asn Ser Met Ser Val Phe Tyr Asp Ala Gly Leu Leu Phe Glu Ser
625 630 635 640
Ser Ala Ala Ser Gly Thr Pro Tyr Arg Gln Glu Leu Lys Cys Pro Val
645 650 655
Pro Ala Arg Arg Lys Arg Ala Thr Thr Val Met Asn Val Thr Thr Thr
660 665 670
Leu Val Asn Lys Tyr Lys Asn Glu Leu Gln Arg Glu Cys Cys Ser Glu
675 680 685
Gly Met Lys Glu Thr Ile Leu Ser Tyr Thr Cys Glu Val Arg Ser Glu
690 695 700
Tyr Ile Leu Asp Gly Ala Ser Cys Val Asp Ala Phe Leu His Cys Cys
705 710 715 720
Lys Glu Met Glu Asn Leu Arg Gly Glu Met Lys Gln Asp Gln Leu Asp
725 730 735
Leu Ala Arg Ser Glu Glu Asp Asp Ser Tyr Met Asp Ser Asn Glu Ile
740 745 750
Ser Ser Arg Thr Lys Phe Pro Glu Ser Trp Leu Trp Ser Asp Ile Gln
755 760 765
Leu Pro Ala Cys Pro Gln Gln Thr Pro Asn Cys Glu Ser Thr Ser Phe
770 775 780
Met Lys Pro Val Pro Leu Gln Asp Ser Ile Thr Thr Trp Gln Phe Thr
785 790 795 800
Gly Ile Ser Leu Ser Arg Thr His Gly Ile Cys Val Gly Glu Pro Leu
805 810 815
Glu Val Ile Val Arg Lys Asp Phe Phe Ile Asp Leu Arg Leu Pro Tyr
820 825 830
Ser Ala Val Arg Gly Glu Gln Leu Glu Ile Lys Ala Ile Leu His Asn
835 840 845
Tyr Ser Pro Asp Val Ile Thr Val Arg Val Asp Leu Ile Glu Glu Glu
850 855 860
Asn Val Cys Ser Val Ala Ser Lys His Thr Arg Tyr Arg Gln Glu Val
865 870 875 880
Lys Val Gly Gln Gln Thr Thr Arg Ser Val Pro Phe Val Ile Ile Pro
885 890 895
Met Lys Glu Gly Gln Phe Asn Ile Glu Val Lys Ala Ala Val Lys Asp
900 905 910
Ser Ser Leu Asn Asp Gly Ile Val Lys Val Leu Arg Val Val Pro Glu
915 920 925
Gly Val Leu Ile Lys Gln Pro Gln Ile Ile Thr Leu Asp Pro Ser Lys
930 935 940
Thr Gly Gly Glu Gln Val Glu Ile Leu Asn Ser Arg Ile Pro Arg Lys
945 950 955 960
Asp Met Val Pro Asn Thr Pro Thr Thr Thr Gln Ile Ser Val Thr Gly
965 970 975
Arg Glu Asn Val Gly Gln Leu Val Glu Asn Ala Ile Ser Gly Gln Ser
980 985 990
Met Gly Thr Leu Ile Tyr Gln Pro Ser Gly Cys Gly Glu Gln Asn Met
995 1000 1005
Ile His Met Thr Leu Pro Val Ile Ala Ala Thr Tyr Leu Asp Lys Thr
1010 1015 1020
Asn Gln Trp Glu Thr Val Gly Phe Gln Lys Arg Asn Glu Ala Leu Gln
1025 1030 1035 1040
His Ile Lys Thr Gly Tyr Thr Asn Glu Leu Ala Tyr Arg Lys Lys Asp
1045 1050 1055
Gly Ser Phe Ser Val Trp Ala Ser His Gly Ser Ser Ser Trp Leu Thr
1060 1065 1070
Ala Tyr Val Ala Lys Val Phe Ala Met Ala Asn Ser Leu Val Ala Val
1075 1080 1085
Gln Asn Asn Val Ile Cys Asp Ala Val Lys Tyr Leu Ile Leu Asn Ala
1090 1095 1100
Gln Gln Pro Asp Gly Val Phe Lys Glu Val Gly Arg Val Ala His Gly
1105 1110 1115 1120
Glu Met Ile Gly Asp Val Arg Gly Thr Asp Ser Glu Ala Ser Met Thr
1125 1130 1135
Ala Phe Cys Leu Ile Ala Met Gln Glu Ser Arg Thr Leu Cys Ala Ala
1140 1145 1150
Thr Val Asn Ser Leu Pro Gly Ser Val Glu Lys Ser Val Leu Tyr Leu
1155 1160 1165
Glu Arg Arg Leu Glu Ser Leu Thr Asn Pro Tyr Ala Val Ala Ile Thr
1170 1175 1180
Ser Tyr Ala Leu Ala Asn Glu Gly Arg Leu Asn Lys Asp Val Leu Tyr
1185 1190 1195 1200
Lys Phe Ala Ser Pro Glu Leu Ser His Trp Pro Val Pro Lys Gly Arg
1205 1210 1215
Val Tyr Thr Leu Glu Ala Thr Ala Tyr Ala Leu Leu Ala Leu Val Lys
1220 1225 1230
Thr Lys Asp Phe Glu Lys Ala Arg Pro Ile Val Arg Trp Phe Ser Gln
1235 1240 1245
Gln Gln Lys Val Gly Gly Gly Tyr Gly Ser Thr Gln Ala Thr Ile Ile
1250 1255 1260
Val Tyr Gln Ala Val Ala Glu Tyr Trp Ala Ala Ala Lys Glu Pro Glu
1265 1270 1275 1280
Tyr Asp Leu Asn Val Asp Ile Leu Leu Pro Gly Arg Ser Lys Pro Glu
1285 1290 1295
Lys Ile Val Leu Asn Ala Asp Asn Ser Tyr Thr Thr Arg Thr Ser Lys
1300 1305 1310
Ile Asn Asp Ile Asn Gln Asp Val Lys Val Thr Ala Lys Gly Thr Gly
1315 1320 1325
Glu Ala Thr Val Thr Met Val Ser Leu Tyr Tyr Ala Leu Pro Gln Lys
1330 1335 1340
Lys Glu Ser Asp Cys Gln Lys Phe Asn Met Ser Val Glu Leu Ile Pro
1345 1350 1355 1360
Glu Arg Ile Asp Ala Asp Glu Ser Ile Phe Lys Leu Lys Ile Glu Val
1365 1370 1375
Leu Tyr Lys Asp Lys Glu Arg Asp Ala Thr Met Ser Ile Leu Asp Ile
1380 1385 1390
Gly Leu Leu Thr Gly Phe Thr Pro Asn Thr Asn Asp Leu Asn Leu Leu
1395 1400 1405
Ser Lys Gly Arg Ala Arg Thr Leu Ala Lys Tyr Glu Met Asn Thr Leu
1410 1415 1420
Leu Ser Glu Lys Gly Ser Leu Ile Ile Tyr Leu Asp Lys Val Ser His
1425 1430 1435 1440
Thr Arg Pro Glu Glu Ile Thr Phe Arg Val His Gln Lys Met Lys Val
1445 1450 1455
Gly Val Leu Gln Pro Ala Ala Val Ser Val Tyr Glu Tyr Tyr Asp Gln
1460 1465 1470
Thr Gln Cys Val Gln Phe Tyr His Pro Gln Arg Lys Ala Gly Gln Leu
1475 1480 1485
Leu Arg Leu Cys Arg Asn Glu Glu Cys Thr Cys Ala Glu Glu Asn Cys
1490 1495 1500
Ser Met Gln Lys Lys Gly Lys Ile Ser Asn Asp Gln Arg Ile Glu Lys
1505 1510 1515 1520
Ser Cys Glu Thr Thr Pro Thr Ser Lys Ile Asp Phe Val Tyr Lys Val
1525 1530 1535
Arg Leu Glu Glu Phe Thr Asp Gly Gly Ser Thr Asp Ile Tyr Thr Met
1540 1545 1550
Arg Ile Leu Glu Gly Ile Lys Glu Gly Ser Tyr Asp Val Ala Pro Gln
1555 1560 1565
Gly Lys Leu Arg Thr Phe Leu Ser Tyr Gln His Cys Arg Glu Ser Leu
1570 1575 1580
Asp Leu Gly Lys Gly Lys Met Tyr Leu Ile Met Gly Thr Ser Lys Asp
1585 1590 1595 1600
Ile His Arg Asp Asp Gln Asn Glu Ser Tyr His Tyr Val Leu Gly Glu
1605 1610 1615
Arg Thr Trp Ile Glu Tyr Trp Pro Thr Glu Ala Glu Cys Gln Thr Glu
1620 1625 1630
Glu His Arg Pro Thr Cys Leu Gly Leu Gln Gln Met Val Gln Gln Tyr
1635 1640 1645
Leu Leu Phe Gly Cys Gln Gln
1650 1655

Claims (6)

1.一种牙鲆补体成分C3的应用，其特征在于：牙鲆补体成分C3(PoC3)在制备杀菌剂中的应用。
2.按权利要求1所述的补体成分C3的应用，其特征在于：所述补体成分C3(PoC3)为序列表SEQ ID No.1中氨基酸序列所示。
3.按权利要求2所述的补体成分C3的应用，其特征在于：所述补体成分C3在制备哈维氏弧菌(Vibrio harveyi)或海豚链球菌(Streptococcus iniae)的杀菌剂中的应用。
4.按权利要求1-3任意一项所述的补体成分C3的应用，其特征在于：所述补体成分C3为以牙鲆血清为原材料，用沉降剂沉降血清，所得蛋白沉淀用20mM Tris-HCL缓冲液(pH 7.4)重悬，将重悬液加入到Mono Q HR5/5阴离子交换色谱柱中，梯度洗脱收集含有C3蛋白的洗脱液进行混合浓缩并重悬在20mM的2-吗啉乙磺酸(MES)(pH 5.8)中，然后将重悬液加入到Mono S HR5/5阳离子交换色谱柱中，梯度洗脱收集含有C3蛋白的洗脱液进行透析浓缩后，即为序列表SEQ ID No.1所示的补体成分C3；
所述沉降剂为终浓度的16％的聚乙二醇、20mM EDTA、10mM苄脒、1mM苯甲基磺酰氟。
5.按权利要求4所述的补体成分C3的应用，其特征在于：所述梯度洗脱时洗脱液为(0-1M)的NaCl溶液。
6.按权利要求4所述的补体成分C3的应用，其特征在于：
1)以阴离子交换色谱柱获得初步纯化的补体成分C3蛋白：
取牙鲆血清与沉降剂等体积混匀，在4℃下沉降30min，收集蛋白沉淀，用20mM Tris-HCL缓冲液(pH 7.4)重悬，将重悬液加入到Mono Q HR5/5阴离子交换色谱柱中，借助高效液相色谱仪，使用NaCl溶液(0-1M)进行梯度洗脱，然后将洗脱液进行聚丙烯酰胺凝胶电泳(SDS-PAGE)分析，并收集含有C3蛋白的洗脱液，即为初步纯化的补体成分C3蛋白；
2)以阳离子交换色谱柱获得纯化完全的补体成分C3蛋白
将上述步骤1)收集的含有C3蛋白的洗脱液进行混合、浓缩并重悬在20mM的2-吗啉乙磺酸(MES)(pH5.8)中，然后将重悬液加入到Mono S HR5/5阳离子交换色谱柱中，用NaCl溶液(0-1M)再次对初步纯化的补体成分C3蛋白进行梯度洗脱，收集洗脱液进行聚丙烯酰胺凝胶电泳(SDS-PAGE)分析，并进行质谱分析，将质谱结果与序列表SEQ ID No.1所示的牙鲆补体成分C3序列进行比对，确定纯化蛋白为牙鲆C3蛋白，最后将含有牙鲆C3蛋白的洗脱液进行透析浓缩后，即为牙鲆补体C3蛋白。
CN202210070638.7A 2022-01-21 2022-01-21 一种牙鲆补体成分C3（PoC3）的应用 Active CN114409756B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210070638.7A CN114409756B (zh) 2022-01-21 2022-01-21 一种牙鲆补体成分C3（PoC3）的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210070638.7A CN114409756B (zh) 2022-01-21 2022-01-21 一种牙鲆补体成分C3（PoC3）的应用

Publications (2)

Publication Number Publication Date
CN114409756A true CN114409756A (zh) 2022-04-29
CN114409756B CN114409756B (zh) 2023-06-09

Family

ID=81274838

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210070638.7A Active CN114409756B (zh) 2022-01-21 2022-01-21 一种牙鲆补体成分C3（PoC3）的应用

Country Status (1)

Country Link
CN (1) CN114409756B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114344450A (zh) * 2022-01-21 2022-04-15 中国科学院海洋研究所 一种牙鲆补体成分C3a蛋白的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009245A1 (en) * 2000-04-03 2004-01-15 Vail William Banning Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US20100062027A1 (en) * 2005-08-10 2010-03-11 Arne Forsgren Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CN102203276A (zh) * 2008-08-27 2011-09-28 奥克兰儿童医院及研究中心 基于补体因子h对脑膜炎奈瑟球菌血清杀菌活性的鉴定
CN102583777A (zh) * 2012-02-29 2012-07-18 中国水产科学研究院淡水渔业研究中心 一种用于防治罗非鱼链球菌病的微生物制剂、其制备方法及应用
CN102813089A (zh) * 2012-08-23 2012-12-12 中国水产科学研究院长江水产研究所 一种罗非鱼养成后期高效配合饲料及制备方法
US20160339066A1 (en) * 2014-01-02 2016-11-24 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN110787289A (zh) * 2019-11-22 2020-02-14 中国科学院海洋研究所 一种补体丝氨酸蛋白酶的应用
CN111527105A (zh) * 2017-10-11 2020-08-11 美国比奥维拉迪维股份有限公司 诱导补体活性的方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009245A1 (en) * 2000-04-03 2004-01-15 Vail William Banning Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US20100062027A1 (en) * 2005-08-10 2010-03-11 Arne Forsgren Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CN102203276A (zh) * 2008-08-27 2011-09-28 奥克兰儿童医院及研究中心 基于补体因子h对脑膜炎奈瑟球菌血清杀菌活性的鉴定
CN102583777A (zh) * 2012-02-29 2012-07-18 中国水产科学研究院淡水渔业研究中心 一种用于防治罗非鱼链球菌病的微生物制剂、其制备方法及应用
CN102813089A (zh) * 2012-08-23 2012-12-12 中国水产科学研究院长江水产研究所 一种罗非鱼养成后期高效配合饲料及制备方法
US20160339066A1 (en) * 2014-01-02 2016-11-24 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN111527105A (zh) * 2017-10-11 2020-08-11 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
CN110787289A (zh) * 2019-11-22 2020-02-14 中国科学院海洋研究所 一种补体丝氨酸蛋白酶的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEI-BEI JIA等: "The trypsin-like serine protease domain of Paralichthys olivaceus complement factor I regulates complement activation and inhibits bacterial growth", vol. 97, pages 18 - 26, XP085997068, DOI: 10.1016/j.fsi.2019.12.019 *
MENG WU等: "Complement C3 and Activated Fragment C3a Are Involved in Complement Activation and Anti-Bacterial Immunity" *
何杰等: "低温驯化下4种不同品系罗非鱼血清皮质醇与免疫相关指标的变化", vol. 21, no. 2 *
李墨非等: "大菱鲆CD55负调控补体激活及其广谱细菌结合能力", vol. 46, no. 7, pages 24 - 31 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114344450A (zh) * 2022-01-21 2022-04-15 中国科学院海洋研究所 一种牙鲆补体成分C3a蛋白的应用
CN114344450B (zh) * 2022-01-21 2023-06-27 中国科学院海洋研究所 一种牙鲆补体成分C3a蛋白的应用

Also Published As

Publication number Publication date
CN114409756B (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
JPH01502397A (ja) Ｍ―ｃｓｆの生産方法
EA035163B1 (ru) Препарат очищенной рекомбинантной гиалуронидазы, способ его производства и содержащие его композиции
RU2401307C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFK2, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО ПЕПТИДА, ЯВЛЯЮЩЕГОСЯ АНАЛОГОМ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ПЕПТИДА И РЕКОМБИНАНТНЫЙ ПЕПТИД, АНАЛОГ ФРАГМЕНТА КАППА-КАЗЕИНА ЧЕЛОВЕКА, ОБЛАДАЮЩИЙ АПОПТОТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РАКОВЫМ КЛЕТКАМ
CN114409756B (zh) 一种牙鲆补体成分C3（PoC3）的应用
CN110684760A (zh) 一种杀灭葡萄球菌的基因工程裂解酶及制备方法和应用
CN102633867A (zh) 抗原性改变的肠毒素c2突变体及编码基因与制备和应用
CN108264548B (zh) 鳜鱼伽玛干扰素相关因子及其重组蛋白和应用
CN112480227B (zh) 一种提高鲟鱼抵抗病原菌能力的蛋白及其制备方法与应用
CN109627316A (zh) 草鱼IFN-γ2基因及其编码的重组蛋白和应用
RU2054044C1 (ru) Способ получения рекомбинантного человеческого свободного от метионина на n-конце гамма-интерферона
CN111529686B (zh) 一种来源于鳜鱼的半乳糖凝集素-9在制备抑菌剂中的应用
CN108484749B (zh) 一种重组可溶性人源骨靶向干扰素γ-1b及其制备方法
CN106868035B (zh) 一种重组马Interferon-alpha-1的制备方法
CN112618698A (zh) 一种人白细胞介素10-Fc融合蛋白的注射制剂
CN110923289B (zh) 一种用于治疗柑橘黄龙病的药物的筛选方法
CN102140444A (zh) 一种低温碱性磷酸酶及其制备方法
US20200040063A1 (en) Process of cloning and further purification to make a recombinant intravenous immunoglobulin
DK171419B1 (da) Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse
JPH0296598A (ja) リンフォカイン活性化キラー細胞誘導抑制因子ｌａｋｓｆ，その製造法およびそれを有効成分とする免疫抑制剤
CN101974536B (zh) 重组人干扰素β1a基因、其表达载体和重组人干扰素β1a的制备方法
CN110606884A (zh) 一种猪α-干扰素的后提取工艺
RU2618850C2 (ru) Плазмидный вектор pET-mChBac75Na, штамм бактерии Eschrichia coli BL21(DE3/ pET-mChBac75Na для экспрессии антимикробного пептида минибактенецина ChBac7.5 Nα и способ получения указанного пептида
CN111053890A (zh) 来源于鳜鱼的半乳糖凝集素-8在制备抑菌剂中的应用
WO1991018925A1 (fr) Nouveau facteur de stimulation de colonies megacaryocytaires et production de ce facteur
CN114990098B (zh) 一种裂解酶、编码基因、组合物、抑菌剂制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant